Complete Filing Data
KAZIA THERAPEUTICS LTD reported Cash And Cash Equivalents of $4.35 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean KAZIA THERAPEUTICS LTD did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profit Loss | -$20.7M | -$26.8M | -$20.5M | -$25.0M | -$8.4M | -$12.5M | -$10.3M | -$6.0M | -$10.7M | -$12.2M |
| Selling General And Administrative Expense | $8.7M | $13.6M | $8.6M | $5.1M | $7.0M | $3.7M | $3.8M | $5.6M | $8.5M | $5.8M |
| Research And Development Expense | $7.3M | $17.4M | $15.6M | $20.2M | $14.5M | $9.5M | $6.5M | $9.8M | $11.1M | $9.9M |
| Profit Loss Before Tax | -$22.4M | -$27.0M | -$20.7M | -$25.4M | -$8.9M | -$12.8M | -$10.6M | -$6.3M | -$10.9M | -$12.2M |
| Other Revenue | $1.8M | $173.0K | $1.0K | $25.0K | $2.0K | $995.0K | $1.5M | $13.0M | $8.6M | $3.7M |
| Other Comprehensive Income Net Of Tax Exchange Differences On Translation | -$23.0K | -$8.0K | $110.0K | $35.0K | $2.0K | -$4.0K | -$89.0K | -$251.0K | $25.0K | -$1.0K |
| Other Comprehensive Income | -$23.0K | -$8.0K | $110.0K | $35.0K | $2.0K | -$4.0K | -$89.0K | -$251.0K | $34.0K | $174.0K |
| Comprehensive Income | -$20.7M | -$26.8M | -$20.4M | -$25.0M | -$8.4M | -$12.5M | -$10.4M | -$6.3M | -$10.6M | -$12.0M |
| Income Tax Expense Continuing Operations | -$1.7M | -$271.0K | -$271.0K | -$368.0K | -$484.0K | -$298.0K | -$298.0K | -$305.0K | -$199.0K | |
| Profit Loss Attributable To Owners Of Parent | -$20.5M | -$25.0M | -$8.4M | -$12.5M | -$10.3M | -$6.0M | -$10.7M | -$12.1M | ||
| Comprehensive Income Attributable To Owners Of Parent | -$20.4M | -$25.0M | -$8.4M | -$12.5M | -$10.4M | -$6.3M | -$10.6M | -$11.9M | ||
| Revenue From Interest | $0.00 | $0.00 | $15.2M | $119.0K | $249.0K | $406.0K | ||||
| Impairment Loss Recognised In Profit Or Loss Property Plant And Equipment | $1.0K | $143.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents | $4.3M | $1.7M | $5.2M | $7.4M | $27.6M | $8.8M | $5.4M | $6.0M | $14.5M | $33.5M | $44.4M |
| Intangible Assets Other Than Goodwill | $1.1M | $0.00 | $17.3M | $19.1M | $21.0M | $12.4M | $13.5M | $14.6M | $15.9M | $822.0K | |
| Cash Flows From Used In Operating Activities | -$13.3M | -$9.6M | -$15.2M | -$22.8M | -$9.1M | -$8.8M | -$6.7M | -$8.7M | -$11.4M | -$12.0M | |
| Cash Flows From Used In Financing Activities | $16.0M | $6.0M | $13.0M | $3.7M | $28.1M | $12.1M | $3.8M | -$18.0K | $782.0K | ||
| Deferred Tax Liabilities | $272.0K | $2.0M | $2.3M | $2.6M | $2.9M | $3.4M | $3.7M | $4.0M | $4.3M | ||
| Trade And Other Current Receivables | $98.0K | $3.9M | $3.9M | $91.0K | $84.0K | $1.4M | $1.7M | $2.5M | $4.3M | ||
| Trade And Other Current Payables | $10.1M | $15.1M | $4.3M | $3.8M | $4.9M | $3.5M | $1.8M | $2.1M | $1.9M | ||
| Retained Earnings | -$134.8M | -$115.1M | -$89.1M | -$68.6M | -$44.2M | -$36.2M | -$24.9M | -$14.6M | -$171.0M | ||
| Other Current Assets | $491.0K | $591.0K | $1.6M | $2.0M | $1.7M | $537.0K | $370.0K | $768.0K | $758.0K | ||
| Noncurrent Liabilities | $309.0K | $5.8M | $8.5M | $10.9M | $13.3M | $3.9M | $5.1M | $5.0M | $5.2M | ||
| Noncurrent Assets | $1.1M | $15.4M | $17.3M | $26.4M | $27.7M | $12.4M | $13.7M | $18.9M | $16.4M | ||
| Liabilities | $14.4M | $31.6M | $16.0M | $17.6M | $19.2M | $8.9M | $7.0M | $8.9M | $10.6M | ||
| Current Liabilities | $14.1M | $25.8M | $7.6M | $6.7M | $6.0M | $5.1M | $1.9M | $3.9M | $5.4M | ||
| Current Assets | $4.9M | $6.1M | $10.8M | $9.4M | $29.4M | $10.7M | $7.5M | $9.3M | $19.5M | ||
| Assets | $6.1M | $21.6M | $28.1M | $35.9M | $57.1M | $23.1M | $21.2M | $28.2M | $35.9M | ||
| Issue Of Equity | $13.4M | $4.2M | $273.0K | $13.0M | $5.4M | $30.0K | $782.0K | ||||
| Cash Flows From Used In Operations Before Changes In Working Capital | -$10.3M | -$19.6M | -$19.5M | -$23.6M | -$3.5M | -$10.5M | -$7.1M | -$10.2M | -$7.5M | -$11.3M | |
| Adjustments For Increase Decrease In Trade And Other Payables | -$5.0M | $10.7M | $569.0K | -$528.0K | $1.0M | $1.7M | -$409.0K | $88.0K | $573.0K | -$328.0K | |
| Adjustments For Decrease Increase In Trade And Other Receivables | $3.8M | $5.0K | $3.5M | -$7.0K | -$5.0M | $358.0K | $825.0K | $1.7M | -$4.0M | $15.0K | |
| Net Assets Liabilities | $12.1M | $18.3M | $37.9M | $14.1M | $14.2M | $19.2M | $25.3M | ||||
| Adjustments For Increase Decrease In Deferred Tax Liabilities | -$1.7M | -$271.0K | -$271.0K | -$368.0K | -$484.0K | -$298.0K | -$298.0K | -$305.0K | -$198.0K | ||
| Other Equity Interest | $380.0K | $0.00 | $0.00 | $0.00 | $464.0K | $464.0K | $464.0K | $464.0K | $600.0K | ||
| Equity Attributable To Owners Of Parent | -$8.3M | -$10.0M | $12.1M | $18.3M | $37.9M | $14.1M | $14.2M | $19.2M | $25.3M | ||
| Other Current Financial Liabilities | $3.2M | $6.5M | $8.6M | ||||||||
| Cash Flows From Used In Investing Activities | $0.00 | $0.00 | -$2.4M | $2.4M | $150.0K | -$7.1M | -$522.0K | ||||
| Noncurrent Receivables | $43.0K | $7.3M | $6.7M | ||||||||
| Gains Losses On Financial Assets At Fair Value Through Profit Or Loss | $0.00 | $0.00 | -$168.0K | -$1.8M | -$1.1M | ||||||
| Gains Losses On Disposals Of Noncurrent Assets | -$1.0K | -$137.0K | -$16.0K | -$2.0K | |||||||
| Adjustments For Increase Decrease In Deferred Income | $0.00 | -$138.0K | $97.0K | $41.0K | |||||||
| Gains Losses On Availableforsale Financial Assets | -$168.0K | -$1.8M | -$3.9M | ||||||||
| Other Noncurrent Receivables | $40.0K | $40.0K | $43.0K | ||||||||
| Gain Loss On Remeasurement Of Other Financial Liability | $2.5M | -$1.3M | $0.00 | $0.00 |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes | $2.7M | -$3.6M | -$2.2M | -$21.4M | $19.0M | $3.3M | -$539.0K | -$8.5M | -$18.6M | -$11.7M |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | -$16.0K | $12.0K | $64.0K | $1.2M | -$175.0K | $17.0K | $12.0K | -$428.0K | $802.0K | |
| Proceeds From Issuing Shares | 11.8M | 2.9M | 13.0M | 3.7M | 28.1M | 12.1M | 3.8M | 853.0K | ||
| Proceeds From Issue Of Equity And Pre Funded Warrants | $3.0M | $2.7M | $0.00 | $0.00 | ||||||
| Proceeds From Borrowings Classified As Financing Activities | $0.00 | $776.0K | $0.00 | $0.00 |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Basic Earnings Loss Per Share | $-0.04 | $-0.10 | $-0.11 | $-0.19 | $-0.07 | $-0.17 | $-17.86 | $-12.48 | $-2.28 | $-2.82 |
| Diluted Earnings Loss Per Share | $-0.04 | $-0.10 | $-0.11 | $-0.19 | $-0.07 | $-0.17 | $-17.86 | $-12.48 | $-2.28 | $-2.82 |
| Diluted Earnings Loss Per Share From Continuing Operations | $-0.11 | $-0.19 | $-0.07 | $-0.17 | $-17.86 | $-12.48 | $-2.28 | |||
| Basic Earnings Loss Per Share From Continuing Operations | $-0.11 | $-0.19 | $-0.07 | $-0.17 | $-17.86 | $-12.48 | $-2.28 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Issued Capital | $123.0M | $101.6M | $97.5M | $84.5M | $80.3M | $48.8M | $36.6M | $31.6M | $193.8M | -$162.2M |
| Other Reserves | $3.1M | $3.5M | $3.7M | $2.4M | $1.3M | $1.1M | $2.0M | $1.8M | $1.9M | |
| Finance Income | $72.0K | $12.0K | $22.0K | $2.0K | $42.0K | $66.0K | $100.0K | |||
| Increase Decrease Through Sharebased Payment Transactions | $1.2M | $1.7M | $637.0K | $262.0K | $246.0K | $165.0K | $1.6M | $372.0K | ||
| Adjustments For Sharebased Payments | $653.0K | $533.0K | $1.2M | $1.7M | $637.0K | $262.0K | $246.0K | $165.0K | $517.0K | $372.0K |
| Adjustments For Provisions | $27.0K | -$349.0K | $264.0K | $201.0K | $92.0K | $55.0K | -$25.0K | -$58.0K | $23.0K | -$29.0K |
| Share Issue Related Cost | $401.0K | $493.0K | $1.7M | $833.0K | $340.0K | $18.0K | ||||
| Contingent Consideration Noncurrent | $0.00 | $3.8M | $6.1M | $8.2M | $10.3M | $458.0K | $1.4M | $1.0M | $704.0K | |
| Contingent Consideration Current | $0.00 | $3.3M | $750.0K | $759.0K | $791.0K | $1.4M | $0.00 | $1.5M | $3.3M | |
| Consideration Paid Received | $7.6M | -$134.0K | $2.1M | $0.00 | -$2.6M | -$474.0K | -$63.0K | $1.5M | -$764.0K | |
| Current Provisions For Employee Benefits | $390.0K | $365.0K | $690.0K | $369.0K | $229.0K | $191.0K | ||||
| Noncurrent Provisions For Employee Benefits | $37.0K | $35.0K | $59.0K | $117.0K | $55.0K | |||||
| Gain Loss On Revaluation Of Contingent Consideration | -$152.0K | -$2.6M | -$474.0K | -$63.0K | ||||||
| Adjustments For Unrealised Foreign Exchange Losses Gains | $310.0K | -$20.0K | $46.0K | -$2.2M | $428.0K | -$251.0K | $454.0K | -$796.0K | ||
| Adjustments For Depreciation And Amortisation Expense | $1.9M | $1.9M | $1.3M | $1.1M | $1.1M | $1.5M | $1.4M | $643.0K | ||
| Adjustments For Decrease Increase In Prepayments | $365.0K | -$277.0K | -$1.2M | -$168.0K | $398.0K | -$10.0K | -$325.0K | -$307.0K | ||
| Shortterm Borrowings | $396.0K | $634.0K | $1.8M | $1.8M | $0.00 | |||||
| Repayments Of Borrowings Classified As Financing Activities | $0.00 | $371.0K | $253.0K | $0.00 | ||||||
| Gain Loss On Remeasurement Of Contingent Consideration | $7.6M | $119.0K | $3.4M | $0.00 | -$2.6M | |||||
| Commercialisation | $0.00 | $0.00 | $127.0K | $0.00 | $0.00 | |||||
| Increase Decrease Through Conversion Of Convertible Instruments | $0.00 | $380.0K | $0.00 | $0.00 | ||||||
| Adjustment For Increase Decrease In Borrowings Current | -$238.0K | -$1.2M | -$45.0K | $1.8M | ||||||
| Payment Of Milestone Relating To Contingent Consideration Classified As Investing Activities | $0.00 | $0.00 | $2.4M | |||||||
| Gain Loss On Remeasurement Of Promissory Note | $0.00 | -$25.0K | $0.00 | $0.00 |
Most recent annual filing with the SEC: November 7, 2025
Data sourced from SEC EDGAR public filings as of August 6, 2026.